Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson tells Proactive's Stephen Gunnion that 2025 was a transformational year, marked by the acquisition of Awakn Life Sciences, a strategic rebrand, and a sharp refocus on high-burden CNS disorders.
The centrepiece of the conversation is lead programme SVN-001 and the decision to take it through phase III rather than pursue an early licensing deal. Tennyson is direct about the rationale: shareholder value is greater at the end of a successful phase III than before it.
Phase II data for SVN-001 in severe alcohol use disorder showed meaningfully improved sobriety outcomes, and the broader pipeline — including SVN-002 and early-stage asset SVN-015 — continues to advance across addiction and psychiatry. Tennyson also flags improving conditions in the US, with growing regulatory and investor support providing a useful tailwind for the sector.
For more insights and updates on emerging biotech companies, visit Proactive’s YouTube channel, like
this video, subscribe, and enable notifications so you never miss future content.
#SolvonisTherapeutics #BiotechPipeline #CNSDisorders #DrugDevelopment #SVN001 #AlcoholUseDisorder #BiotechInvesting #PharmaInnovation #ClinicalTrials #HealthcareInnovation #AddictionTreatment #BiotechNews
